242 related articles for article (PubMed ID: 20334445)
1. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment and cost of cardiovascular disease in Australia.
Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
[TBL] [Abstract][Full Text] [Related]
3. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
[TBL] [Abstract][Full Text] [Related]
4. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
[TBL] [Abstract][Full Text] [Related]
5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
7. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
8. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.
Balu S; Simko RJ; Quimbo RM; Cziraky MJ
Curr Med Res Opin; 2009 Nov; 25(11):2765-75. PubMed ID: 19785511
[TBL] [Abstract][Full Text] [Related]
9. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
10. One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
Mahoney EM; Wang K; Cohen DJ; Hirsch AT; Alberts MJ; Eagle K; Mosse F; Jackson JD; Steg PG; Bhatt DL;
Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):38-45. PubMed ID: 20031786
[TBL] [Abstract][Full Text] [Related]
11. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
Carrington M; Stewart S
Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
[TBL] [Abstract][Full Text] [Related]
12. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
13. Medical care costs among patients with established cardiovascular disease.
Nichols GA; Bell TJ; Pedula KL; O'Keeffe-Rosetti M
Am J Manag Care; 2010 Mar; 16(3):e86-e93. PubMed ID: 20205493
[TBL] [Abstract][Full Text] [Related]
14. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
[TBL] [Abstract][Full Text] [Related]
15. Risk-factor clustering and cardiovascular disease risk in hypertensive patients.
Weycker D; Nichols GA; O'Keeffe-Rosetti M; Edelsberg J; Khan ZM; Kaura S; Oster G
Am J Hypertens; 2007 Jun; 20(6):599-607. PubMed ID: 17531915
[TBL] [Abstract][Full Text] [Related]
16. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
17. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
Shah M; Butler M; Bramley T; Curtice TG; Fine S
Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of lipid-lowering treatment according to lipid level.
Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA
Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451
[TBL] [Abstract][Full Text] [Related]
19. [The best of epidemiology and cardiovascular prevention in 2006].
Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
[TBL] [Abstract][Full Text] [Related]
20. The impact of prevention on reducing the burden of cardiovascular disease.
Kahn R; Robertson RM; Smith R; Eddy D
Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
